Indications and limitations of use of Upadacitinib

UpadacitinibAdapt is aJanuskinase(JAK) inhibitor.

For treatment:

1.Adults with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or moreTNFblockers.

Usage restrictions:

It is not recommended to use upatinib in combination with other JAKinhibitors, biological DMARDs or strong immunosuppressants (such as azathioprine and cyclosporine ).

2.Adults with active psoriatic arthritis who have an inadequate response to or intolerance to one or moreTNFblockers.

Usage restrictions:

It is not recommended to use upatinib in combination with other JAKinhibitors, biological DMARDs or strong immunosuppressants (such as azathioprine and cyclosporine ).

3.Adult and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease cannot be adequately controlled with other systemic medications (including biologics)or whose use is not recommended.

Usage restrictions:

Concomitant useupadatinibwith otherJAKinhibitors, biologic immunomodulators, or other immunosuppressants is not recommended.

4.For one or moreTNFAdults with moderately to severely active ulcerative colitis who have inadequate response to or intolerance to blockers.

Usage restrictions:

Usingupatinib in combination with otherJAKinhibitors, biological therapies for ulcerative colitis, or strong immunosuppressives (such as azathioprine and cyclosporine) is not recommended.

5.Adults with moderately to severely active Crohn's disease who have an inadequate response to or are intolerant to one or moreTNFblockers.

Usage restrictions:

It is not recommended to useupatinib in combination with otherJAKinhibitors, biological therapies for Crohn's disease, or strong immunosuppressives (such as azathioprine and cyclosporine).

6.Adult patients with active ankylosing spondylitis who have an inadequate response to or intolerance to one or moreTNF blockers.

Usage restrictions

It is not recommended to use upatinib in combination with other JAKinhibitors, biological DMARDs or strong immunosuppressants (such as azathioprine and cyclosporine ).

7.Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have an inadequate response to or intolerance to tumor necrosis factor blocker therapy.

Usage restrictions:

It is not recommended to use upatinib in combination with other JAKinhibitors, biological DMARDs or strong immunosuppressants (such as azathioprine and cyclosporine ).

The metabolism of upadatinib is mainly mediated byCYP3A4, and CYP2D6 may also be involved to a small extent. The pharmacological activity of upadatinib is attributed to the parent molecule. In a human radiolabeling study, unchanged upapatinib accounted for 79% of the total radioactivity in plasma, and the major metabolite detected was (The products of glucuronidation after monooxidation)account for 13% of the total plasma radioactivity. No active metabolites of upapatinib have been identified. There are generic drugs in Bangladesh, and the retail price of Bangladesh Yaopin International Pharmaceuticals is more than 100 for 15 mg of 30 tablets. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0

xa0